Allopregnanolone preclinical acute pharmacokinetic and pharmacodynamic studies to predict tolerability and efficacy for alzheimer's disease

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Irwin, Ronald W ^a   Solinsky, Christine M ^a   Loya, Carlos M ^b   Salituro, Francesco G ^b   Rodgers, Kathleen E ^a   Bauer, Gerhard ^c   Rogawski, Michael A ^c   Brinton, Roberta Diaz ^a,d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Sage Therapeutics Inc   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; BETA CYCLODEXTRIN SULFOBUTYL ETHER; BROXURIDINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLINE; NEUROGENIC DIFFERENTIATION FACTOR; BIOLOGICAL MARKER; CYCLODEXTRIN; ELTANOLONE;

ADULT; ADVERSE OUTCOME; AGING; ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EMBRYO; FEMALE; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM DEVELOPMENT; NEW ZEALAND WHITE (RABBIT); NONHUMAN; OUTCOME ASSESSMENT; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SEDATION; SEX DIFFERENCE; THIRD TRIMESTER PREGNANCY; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BRAIN; C57BL MOUSE; CELL DIFFERENTIATION; CHEMISTRY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; HUMAN; MAXIMUM TOLERATED DOSE; METABOLISM; NO-OBSERVED-ADVERSE-EFFECT LEVEL; PATHOLOGY; PHOSPHORYLATION; PRECLINICAL STUDY; RABBIT; SPRAGUE DAWLEY RAT; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ANIMALIA; MUS; ORYCTOLAGUS CUNICULUS; RATTUS;

ALZHEIMER DISEASE; ANIMALS; BIOMARKERS; BRAIN; BROMODEOXYURIDINE; CELL DIFFERENTIATION; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLODEXTRINS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEUROGENESIS; NO-OBSERVED-ADVERSE-EFFECT LEVEL; PHOSPHORYLATION; PREGNANOLONE; PROLIFERATING CELL NUCLEAR ANTIGEN; RABBITS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME;

EID: 84934967378     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0128313     Document Type: Article

References (59)

1. Alzheimer's-Association. Alzheimer's Disease Facts and Figures. 2013.
2. Irwin RW, Solinsky CM, Brinton RD. Frontiers in therapeutic development of allopregnanolone for Alzheimer's disease and other neurological disorders. Frontiers in cellular neuroscience. 2014; 8:203. Epub 2014/08/16. doi: 10.3389/fncel.2014.00203 PMID: 25126056; PubMed Central PMCID: PMC4115668.
3. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014; 370(4):311-21. Epub 2014/01/24. doi: 10.1056/NEJMoa1312889 PMID: 24450890.
4. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014; 370(4):322-33. Epub 2014/01/24. doi: 10.1056/NEJMoa1304839 PMID: 24450891.
5. Brinton RD. Neurosteroids as regenerative agents in the brain: therapeutic implications. Nat Rev Endocrinol. 2013; 9(4):241-50. Epub 2013/02/27. doi: 10.1038/nrendo.2013.31 PMID: 23438839.
6. Lazarov O, Marr RA. Of mice and men: neurogenesis, cognition and Alzheimer's disease. Frontiers in aging neuroscience. 2013; 5:43. Epub 2013/08/30. doi: 10.3389/fnagi.2013.00043 PMID: 23986699; PubMed Central PMCID: PMC3753540.
7. Knoth R, Singec I, Ditter M, Pantazis G, Capetian P, Meyer RP, et al. Murine features of neurogenesis in the human hippocampus across the lifespan from 0 to 100 years. PLoS One. 2010; 5(1):e8809. Epub 2010/02/04. doi: 10.1371/journal.pone.0008809 PMID: 20126454; PubMed Central PMCID: PMC2813284.
8. Spalding KL, Bergmann O, Alkass K, Bernard S, Salehpour M, Huttner HB, et al. Dynamics of hippocampal neurogenesis in adult humans. Cell. 2013; 153(6):1219-27. Epub 2013/06/12. doi: 10.1016/j.cell.2013.05.002 PMID: 23746839.
9. Ernst A, Alkass K, Bernard S, Salehpour M, Perl S, Tisdale J, et al. Neurogenesis in the striatum of the adult human brain. Cell. 2014; 156(5):1072-83. Epub 2014/02/25. doi: 10.1016/j.cell.2014.01.044 PMID: 24561062.
10. Wang JM, Singh C, Liu L, Irwin RW, Chen S, Chung EJ, et al. Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2010; 107 (14):6498-503. Epub 2010/03/17. Doi: 1001422107 [pii] doi: 10.1073/pnas.1001422107 PMID: 20231471; PubMed Central PMCID: PMC2851948.
11. Wang JM, Johnston PB, Ball BG, Brinton RD. The neurosteroid allopregnanolone promotes proliferation of rodent and human neural progenitor cells and regulates cell-cycle gene and protein expression. J Neurosci. 2005; 25(19):4706-18. PMID: 15888646.
12. Chen S, Wang JM, Irwin RW, Yao J, Liu L, Brinton RD. Allopregnanolone Promotes Regeneration and Reduces beta-Amyloid Burden in a Preclinical Model of Alzheimer's Disease. PLoS One. 2011; 6(8):e24293. Epub 2011/09/16. doi: 10.1371/journal.pone.0024293 PMID: 21918687; PubMed Central PMCID: PMC3168882.
13. Singh C, Liu L, Wang JM, Irwin RW, Yao J, Chen S, et al. Allopregnanolone restores hippocampal-dependent learning and memory and neural progenitor survival in aging 3xTgAD and nonTg mice. Neurobiol Aging. 2011. Epub 2011/08/02. doi: 10.1016/j.neurobiolaging.2011.06.008 PMID: 21803451.
14. Irwin RW, Wang JM, Chen S, Brinton RD. Neuroregenerative mechanisms of allopregnanolone in Alzheimer's disease. Front Endocrinol (Lausanne). 2011; 2:117. Epub 2011/01/01. doi: 10.3389/fendo.2011.00117 PMID: 22654847; PubMed Central PMCID: PMC3356095.
15. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. Journal of pharmacological and toxicological methods. 2000; 44(1):235-49. Epub 2001/03/29. PMID: 11274893.
16. Grant KA, Helms CM, Rogers LS, Purdy RH. Neuroactive steroid stereospecificity of ethanol-like discriminative stimulus effects in monkeys. The Journal of pharmacology and experimental therapeutics. 2008; 326(1):354-61. PMID: 18436788. doi: 10.1124/jpet.108.137315
17. Kask K, Backstrom T, Lundgren P, Sundstrom Poromaa I. Allopregnanolone has no effect on startle response and prepulse inhibition of startle response in patients with premenstrual dysphoric disorder or healthy controls. Pharmacol Biochem Behav. 2009; 92(4):608-13. Epub 2009/03/10. doi: S0091-3057(09)00079-3 [pii] doi: 10.1016/j.pbb.2009.02.014 PMID: 19268499.
18. Kask K, Backstrom T, Nilsson LG, Sundstrom-Poromaa I. Allopregnanolone impairs episodic memory in healthy women. Psychopharmacology (Berl). 2008; 199(2):161-8. Epub 2008/06/14. doi: 10.1007/s00213-008-1150-7 PMID: 18551282.
19. Luisi S, Petraglia F, Benedetto C, Nappi RE, Bernardi F, Fadalti M, et al. Serum allopregnanolone levels in pregnant women: changes during pregnancy, at delivery, and in hypertensive patients. J Clin Endocrinol Metab. 2000; 85(7):2429-33. Epub 2000/07/21. PMID: 10902789.
20. Timby E, Balgard M, Nyberg S, Spigset O, Andersson A, Porankiewicz-Asplund J, et al. Pharmacokinetic and behavioral effects of allopregnanolone in healthy women. Psychopharmacology (Berl). 2006; 186(3):414-24. Epub 2005/09/24. doi: 10.1007/s00213-005-0148-7 PMID: 16177884.
21. van Broekhoven F, Backstrom T, van Luijtelaar G, Buitelaar JK, Smits P, Verkes RJ. Effects of allopregnanolone on sedation in men, and in women on oral contraceptives. Psychoneuroendocrinology. 2007; 32(5):555-64. Epub 2007/05/02. doi: 10.1016/j.psyneuen.2007.03.009 PMID: 17470385.
22. Wang JM, Brinton RD. Allopregnanolone-induced rise in intracellular calcium in embryonic hippocampal neurons parallels their proliferative potential. BMC Neurosci. 2008; 9 Suppl 2:S11. Epub 2009/01/06. doi: 1471-2202-9-S2-S11 [pii] doi: 10.1186/1471-2202-9-S2-S11 PMID: 19090984; PubMed Central PMCID: PMC2604895.
23. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003; 39(3):409-21. Epub 2003/08/05. PMID: 12895417.
24. Caruso D, Pesaresi M, Maschi O, Giatti S, Garcia-Segura LM, Melcangi RC. Effect of short-and longterm gonadectomy on neuroactive steroid levels in the central and peripheral nervous system of male and female rats. J Neuroendocrinol. 2010; 22(11):1137-47. Epub 2010/09/08. doi: 10.1111/j.1365-2826.2010.02064.x PMID: 20819120.
25. Caruso D, Barron AM, Brown MA, Abbiati F, Carrero P, Pike CJ, et al. Age-related changes in neuroactive steroid levels in 3xTg-AD mice. Neurobiol Aging. 2013; 34(4):1080-9. Epub 2012/11/06. doi: 10.1016/j.neurobiolaging.2012.10.007 PMID: 23122920; PubMed Central PMCID: PMC3545103.
26. Henry S, Bigler S, Wang J. High throughput analysis of neural progenitor cell proliferation in adult rodent hippocampus. Bioscience trends. 2009; 3(6):233-8. Epub 2010/01/28. PMID: 20103852; PubMed Central PMCID: PMC2830061.
27. Bilsland JG, Haldon C, Goddard J, Oliver K, Murray F, Wheeldon A, et al. A rapid method for the quantification of mouse hippocampal neurogenesis in vivo by flow cytometry. Validation with conventional and enhanced immunohistochemical methods. Journal of neuroscience methods. 2006; 157(1):54-63. Epub 2006/08/01. doi: 10.1016/j.jneumeth.2006.03.026 PMID: 16876875.
28. Friedemann MN, Gerhardt GA. Regional effects of aging on dopaminergic function in the Fischer-344 rat. Neurobiol Aging. 1992; 13(2):325-32. Epub 1992/03/01. PMID: 1522947.
29. Wallace JE, Krauter EE, Campbell BA. Motor and reflexive behavior in the aging rat. Journal of gerontology. 1980; 35(3):364-70. Epub 1980/05/01. PMID: 7410787.
30. Stella VJ, He Q. Cyclodextrins. Toxicol Pathol. 2008; 36(1):30-42. Epub 2008/03/14. doi: 10.1177/0192623307310945 PMID: 18337219.
31. Ben-Ari Y, Gaiarsa JL, Tyzio R, Khazipov R. GABA: a pioneer transmitter that excites immature neurons and generates primitive oscillations. Physiological reviews. 2007; 87(4):1215-84. Epub 2007/10/12. doi: 10.1152/physrev.00017.2006 PMID: 17928584.
32. Gleeson JG, Lin PT, Flanagan LA, Walsh CA. Doublecortin is a microtubule-associated protein and is expressed widely by migrating neurons. Neuron. 1999; 23(2):257-71. Epub 1999/07/10. PMID: 10399933.
33. Rao MS, Hattiangady B, Shetty AK. The window and mechanisms of major age-related decline in the production of new neurons within the dentate gyrus of the hippocampus. Aging Cell. 2006; 5(6):545-58. Epub 2006/11/30. doi: ACE243 [pii] doi: 10.1111/j.1474-9726.2006.00243.x PMID: 17129216.
34. Couillard-Despres S, Winner B, Schaubeck S, Aigner R, Vroemen M, Weidner N, et al. Doublecortin expression levels in adult brain reflect neurogenesis. Eur J Neurosci. 2005; 21(1):1-14. Epub 2005/01/19. doi: 10.1111/j.1460-9568.2004.03813.x PMID: 15654838.
35. Miyata T, Maeda T, Lee JE. NeuroD is required for differentiation of the granule cells in the cerebellum and hippocampus. Genes Dev. 1999; 13(13):1647-52. Epub 1999/07/10. PMID: 10398678; PubMed Central PMCID: PMC316850.
36. FDA-CDER. Guidance for industry: Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. 2005.
37. ClinicalTrials.gov. Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD [online] 2014. Available from: http://clinicaltrials.gov/show/NCT02221622.
38. Griffin LD, Gong W, Verot L, Mellon SH. Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone. Nature medicine. 2004; 10(7):704-11. Epub 2004/06/23. doi: 10.1038/nm1073 PMID: 15208706.
39. Zampieri S, Mellon SH, Butters TD, Nevyjel M, Covey DF, Bembi B, et al. Oxidative stress in NPC1 deficient cells: protective effect of allopregnanolone. J Cell Mol Med. 2009; 13(9B):3786-96. Epub 2008/ 09/09. doi: JCMM493 [pii] doi: 10.1111/j.1582-4934.2008.00493.x PMID: 18774957; PubMed Central PMCID: PMC2832077.
40. Zolkowska D, Dhir A, Cooke GR, Wu C, Zhu L, Wulff H, et al. Anticonvulsant activity of intravenous and intramuscular allopregnenalone. Epilepsy Curr. 2013; 13(Suppl.1):11 (Abst 1.023).
41. Rogawski MA, Loya CM, Reddy K, Zolkowska D, Lossin C. Neuroactive steroids for the treatment of status epilepticus. Epilepsia. 2013; 54 Suppl 6:93-8. Epub 2013/09/06. doi: 10.1111/epi.12289 PMID: 24001085; PubMed Central PMCID: PMC3772544.
42. Magnaghi V, Parducz A, Frasca A, Ballabio M, Procacci P, Racagni G, et al. GABA synthesis in Schwann cells is induced by the neuroactive steroid allopregnanolone. J Neurochem. 2010; 112(4):980-90. Epub 2009/12/01. doi: 10.1111/j.1471-4159.2009.06512.x PMID: 19943853.
43. Lepski G, Jannes CE, Nikkhah G, Bischofberger J. cAMP promotes the differentiation of neural progenitor cells in vitro via modulation of voltage-gated calcium channels. Frontiers in cellular neuroscience. 2013; 7:155. Epub 2013/09/26. doi: 10.3389/fncel.2013.00155 PMID: 24065885; PubMed Central PMCID: PMC3777016.
44. Redmond L, Kashani AH, Ghosh A. Calcium regulation of dendritic growth via CaM kinase IV and CREB-mediated transcription. Neuron. 2002; 34(6):999-1010. Epub 2002/06/28. PMID: 12086646.
45. D'Ascenzo M, Piacentini R, Casalbore P, Budoni M, Pallini R, Azzena GB, et al. Role of L-type Ca2+ channels in neural stem/progenitor cell differentiation. Eur J Neurosci. 2006; 23(4):935-44. Epub 2006/03/08. doi: 10.1111/j.1460-9568.2006.04628.x PMID: 16519658.
46. Ramirez M, Hernandez-Montoya J, Sanchez-Serrano SL, Ordaz B, Ferraro S, Quintero H, et al. GABA-mediated induction of early neuronal markers expression in postnatal rat progenitor cells in culture. Neuroscience. 2012; 224:210-22. Epub 2012/09/04. doi: 10.1016/j.neuroscience.2012.08.044 PMID: 22940108.
47. Luke DR, Tomaszewski K, Damle B, Schlamm HT. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). Journal of pharmaceutical sciences. 2010; 99(8):3291-301. Epub 2010/03/10. doi: 10.1002/jps.22109 PMID: 20213839.
48. Lancel M, Faulhaber J, Schiffelholz T, Romeo E, Di Michele F, Holsboer F, et al. Allopregnanolone affects sleep in a benzodiazepine-like fashion. The Journal of pharmacology and experimental therapeutics. 1997; 282(3):1213-8. Epub 1997/10/08. PMID: 9316828.
49. Damianisch K, Rupprecht R, Lancel M. The influence of subchronic administration of the neurosteroid allopregnanolone on sleep in the rat. Neuropsychopharmacology. 2001; 25(4):576-84. Epub 2001/09/15. doi: 10.1016/S0893-133X(01)00242-1 PMID: 11557171.
50. Juptner M, Hiemke C. Sex differences in GABAA receptor binding in rat brain measured by an improved in vitro binding assay. Experimental brain research. 1990; 81(2):297-302. Epub 1990/01/01. PMID: 2168842.
51. Steinmetz KL, Spack EG. The basics of preclinical drug development for neurodegenerative disease indications. BMC Neurol. 2009; 9 Suppl 1:S2. Epub 2009/06/26. doi: 10.1186/1471-2377-9-S1-S2 PMID: 19534731; PubMed Central PMCID: PMC2697630.
52. Purdy RH, Morrow AL, Moore PH Jr., Paul SM. Stress-induced elevations of gamma-aminobutyric acid type A receptor-active steroids in the rat brain. Proc Natl Acad Sci U S A. 1991; 88(10):4553-7. Epub 1991/05/25. PMID: 1852011; PubMed Central PMCID: PMC51699.
53. Girdler SS, Straneva PA, Light KC, Pedersen CA, Morrow AL. Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biol Psychiatry. 2001; 49(9):788-97. Epub 2001/05/02. PMID: 11331087.
54. Marx CE, VanDoren MJ, Duncan GE, Lieberman JA, Morrow AL. Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. Neuropsychopharmacology. 2003; 28(1):1-13. Epub 2002/12/24. doi: 10.1038/sj.npp.1300015 PMID: 12496935.
55. Girdler SS, Lindgren M, Porcu P, Rubinow DR, Johnson JL, Morrow AL. A history of depression in women is associated with an altered GABAergic neuroactive steroid profile. Psychoneuroendocrinology. 2012; 37(4):543-53. Epub 2011/09/06. doi: 10.1016/j.psyneuen.2011.08.004 PMID: 21890277; PubMed Central PMCID: PMC3233657.
56. Zorumski CF, Paul SM, Izumi Y, Covey DF, Mennerick S. Neurosteroids, stress and depression: potential therapeutic opportunities. Neuroscience and biobehavioral reviews. 2013; 37(1):109-22. Epub 2012/10/23. doi: 10.1016/j.neubiorev.2012.10.005 PMID: 23085210; PubMed Central PMCID: PMC3591791.
57. Weill-Engerer S, David JP, Sazdovitch V, Liere P, Eychenne B, Pianos A, et al. Neurosteroid quantification in human brain regions: comparison between Alzheimer's and nondemented patients. J Clin Endocrinol Metab. 2002; 87(11):5138-43. Epub 2002/11/05. PMID: 12414884.
58. Rogawski MA, inventor; Google Patents, assignee. Edible oils to enhance delivery of orally administered steroids patent WO2013043985 A1. 2013.
59. Irwin RW, Brinton RD. Allopregnanolone as regenerative therapeutic for Alzheimer's disease: Translational development and clinical promise. Prog Neurobiol. 2014; 113:40-55. Epub 2013/09/21. doi: 10.1016/j.pneurobio.2013.08.004 PMID: 24044981.